Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249120 | 0.95 | CASP2 (0.58) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL27998259 | 0.95 | FAAH (0.56) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL22923620 | 0.93 | FAAH (0.59) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL28340110 | 0.93 | CASP2 (0.61) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL28393843 | 0.93 | CASP2 (0.61) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL21155006 | 0.93 | CASP2 (0.56) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL20206555 | 0.93 | CNR1 (0.56) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL24810920 | 0.91 | CASP2 (0.65) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL10345068 | 0.91 | CASP2 (0.65) | FAAHCNR1CASP2DNM1NAAA | |
| SCHEMBL23843180 | 0.91 | CASP2 (0.65) | FAAHCNR1CASP2DNM1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200056185-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927372-B2 | Compositions and methods for modulating apolipoprotein C-III expression | APOB, APOL1, LDLR | FAAH 3575/4885CNR1 2706/4885CASP2 3321/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | FAAH 3527/4885CNR1 1841/4885CASP2 4504/4885 |
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | FAAH 4609/4885CNR1 3267/4885CASP2 4345/4885 |
| US-20210395734-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOB, APOL1, LDLR | FAAH 3575/4885CNR1 2706/4885CASP2 3321/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | FAAH 1637/4885CNR1 4620/4885CASP2 3774/4885 |
| US-20200056185-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | GCKR, PKM, PKLR | FAAH 3367/4885CNR1 3833/4885CASP2 4530/4885 |
| US-10751419-B2 | Method for synthesis of reactive conjugate clusters | ACOT7, COASY, LCAT | FAAH 1637/4885CNR1 4620/4885CASP2 3774/4885 |
| US-20190209694-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | FAAH 1637/4885CNR1 4620/4885CASP2 3774/4885 |
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | FAAH 4670/4885CNR1 4078/4885CASP2 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.